帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好，仅出现轻度胃肠道不良事件，并展现出有前景的活性，值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
人工智能驱动的 TIL（肿瘤浸润淋巴细胞）空间分析作为腺样囊性癌中阿昔替尼的预测性生物标志物
英文原题：Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
查看英文原题
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在复发/转移性 ACC 中，癌区与间质区的 TIL 浸润总体较低。
中文摘要
背景
本研究分析人工智能（AI）驱动的TIL（肿瘤浸润淋巴细胞）分析能否预测阿昔替尼治疗复发或转移性（R/M）腺样囊性癌（ACC）的疗效。
方法
纳入一项评估阿昔替尼治疗R/M ACC疗效的多中心前瞻性II期试验患者。采用Lunit SCOPE IO（一种AI空间TIL分析工具）分析存档肿瘤组织苏木精-伊红全视野图像。
结果
共纳入27例患者。最佳疗效为疾病稳定，中位无进展生存期（PFS）为11.1个月（95% CI 9.2–13.7个月）。癌组织及周围基质的TIL中位密度分别为25.8/mm²（四分位距8.3–73.0）和180.4/mm²（四分位距69.6–342.8）。基质TIL密度>342.5/mm²的患者PFS较长（p=0.012）。
结论
R/M ACC癌组织和基质区域的TIL浸润总体较低；基质TIL浸润较高与阿昔替尼治疗后PFS延长相关。
展开英文摘要原文
BACKGROUND
This study analyzed the predictive value of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) treated with axitinib.
METHODS
Patients from a multicenter, prospective phase II trial evaluating axitinib efficacy in R/M ACC were included in this study. H&E whole-side images of archival tumor tissues were analyzed by Lunit SCOPE IO, an AI-powered spatial TIL analyzer.
RESULTS
Twenty-seven patients were included in the analysis. The best response was stable disease, and the median progression-free survival (PFS) was 11.1 months (95% CI, 9.2-13.7 months). Median TIL densities in the cancer and surrounding stroma were 25.8/mm 2 (IQR, 8.3-73.0) and 180.4/mm 2 (IQR, 69.6-342.8), respectively. Patients with stromal TIL density >342.5/mm 2 exhibited longer PFS (p = 0.012).
CONCLUSIONS
Cancer and stromal area TIL infiltration were generally low in R/M ACC. Higher stromal TIL infiltration was associated with a longer PFS with axitinib treatment.
论文信息
- 作者
- Kim DH、Lim Y、Ock CY、Park G、Park S、Song H、Ma M、Mostafavi M
- 单位
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.South Korea
- 文献类型
- II 期临床试验 · 多中心研究 · 非美国政府资助研究
- 期刊
- Head & neck2023 Dec
- 原文标识
- PubMed 37828867 · DOI 10.1002/hed.27537